

Maria De Santis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9560127/publications.pdf>

Version: 2024-02-01

23
papers

3,306
citations

623188

14
h-index

642321

23
g-index

24
all docs

24
docs citations

24
times ranked

3256
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	1.6	21
2	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	1.6	10
3	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> , 2022, 150, 837-846.	2.3	14
4	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	0.9	33
5	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	0.9	1,545
6	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
7	Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. <i>Immunotherapy</i> , 2021, 13, 125-141.	1.0	72
8	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	0.9	21
9	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	2.6	26
10	Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. <i>Cancer Research</i> , 2021, 81, CT040-CT040.	0.4	8
11	Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. <i>Cancer Research</i> , 2021, 81, CT042-CT042.	0.4	10
12	Abstract CT187: Overall survival (OS) by response during induction from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). <i>Cancer Research</i> , 2021, 81, CT187-CT187.	0.4	3
13	Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with ¹⁷⁷ Lu-labeled prostate-specific membrane antigen. <i>Annals of Nuclear Medicine</i> , 2021, 35, 314-320.	1.2	6
14	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	1.6	131
15	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer: An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132
16	Precision Oncology for Metastatic Prostate Cancer: Translation into Practice. <i>European Urology</i> , 2020, 78, 771-774.	0.9	3
17	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	0.9	101
18	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1043-1053.	0.5	46

#	ARTICLE	IF	CITATIONS
19	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
20	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	0.9	48
21	The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer. <i>ESMO Open</i> , 2019, 4, e000484.	2.0	0
22	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	0.9	8
23	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	0.9	278